Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.

Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W.

Clin Ther. 2012 Apr;34(4):966-78. doi: 10.1016/j.clinthera.2012.02.008. Epub 2012 Mar 7.

PMID:
22401642
2.

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease.

Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B.

BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100.

3.

Epidemiology of restless legs syndrome: a synthesis of the literature.

Ohayon MM, O'Hara R, Vitiello MV.

Sleep Med Rev. 2012 Aug;16(4):283-95. doi: 10.1016/j.smrv.2011.05.002. Epub 2011 Jul 26. Review.

4.

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D; SP710 study group..

Lancet Neurol. 2011 Aug;10(8):710-20. doi: 10.1016/S1474-4422(11)70127-2. Epub 2011 Jun 24.

PMID:
21705273
5.

Algorithms for the diagnosis and treatment of restless legs syndrome in primary care.

Garcia-Borreguero D, Stillman P, Benes H, Buschmann H, Chaudhuri KR, Gonzalez Rodríguez VM, Högl B, Kohnen R, Monti GC, Stiasny-Kolster K, Trenkwalder C, Williams AM, Zucconi M.

BMC Neurol. 2011 Feb 27;11:28. doi: 10.1186/1471-2377-11-28.

6.

[Acute exacerbation of restless legs syndrome during perioperative procedures: case reports and suggested management].

Karroum EG, Raux M, Riou B, Arnulf I.

Ann Fr Anesth Reanim. 2010 Dec;29(12):920-4. doi: 10.1016/j.annfar.2010.09.002. Epub 2010 Nov 26. French.

PMID:
21112730
7.

Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.

Boroojerdi B, Wolff HM, Braun M, Scheller DK.

Drugs Today (Barc). 2010 Jul;46(7):483-505. doi: 10.1358/dot.2010.46.7.1463530. Review.

PMID:
20683503
8.

Transdermal rotigotine for the perioperative management of Parkinson's disease.

Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, Häck HJ, Boroojerdi B, Reichmann H; NEUPOS Study Group..

J Neural Transm (Vienna). 2010 Jul;117(7):855-9. doi: 10.1007/s00702-010-0425-4. Epub 2010 Jun 10.

9.

Restless legs syndrome: pathophysiology, clinical presentation and management.

Trenkwalder C, Paulus W.

Nat Rev Neurol. 2010 Jun;6(6):337-46. doi: 10.1038/nrneurol.2010.55. Review.

PMID:
20531433
10.

Case scenario: anesthetic implications of restless legs syndrome.

Raux M, Karroum EG, Arnulf I.

Anesthesiology. 2010 Jun;112(6):1511-7. doi: 10.1097/ALN.0b013e3181de2d66. Review. No abstract available.

PMID:
20463578
11.

Health economic burden of patients with restless legs syndrome in a German ambulatory setting.

Dodel R, Happe S, Peglau I, Mayer G, Wasem J, Reese JP, Giani G, Geraedts M, Trenkwalder C, Oertel WH, Stiasny-Kolster K.

Pharmacoeconomics. 2010;28(5):381-93. doi: 10.2165/11531030-000000000-00000.

PMID:
20297866
12.

Economic and human costs of restless legs syndrome.

Reinhold T, Müller-Riemenschneider F, Willich SN, Brüggenjürgen B.

Pharmacoeconomics. 2009;27(4):267-79. doi: 10.2165/00019053-200927040-00001. Review.

PMID:
19485424
13.

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Trenkwalder C, Tacken I, Schollmayer E, Kohnen R, Stiasny-Kolster K; Rotigotine SP710 Study Group..

Sleep Med. 2008 Dec;9(8):865-73. doi: 10.1016/j.sleep.2008.04.012. Epub 2008 Aug 26.

PMID:
18753003
14.

Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.

LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J.

Clin Neuropharmacol. 2007 Sep-Oct;30(5):256-65.

PMID:
17909303
15.

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K; Rotigotine SP 709 Study Group..

Sleep Med. 2008 Mar;9(3):228-39. Epub 2007 Jun 5.

PMID:
17553743
16.

Rotigotine transdermal system for perioperative administration.

Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ.

J Neural Transm (Vienna). 2007 Feb;114(2):219-21. Epub 2006 Dec 21.

PMID:
17177076
17.

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C; International Restless Legs Syndrome Study Group..

Sleep Med. 2003 Mar;4(2):121-32.

PMID:
14592342
18.

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J; Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health.; International Restless Legs Syndrome Study Group..

Sleep Med. 2003 Mar;4(2):101-19. Review.

PMID:
14592341
19.

Transient restless legs syndrome after spinal anesthesia: a prospective study.

Högl B, Frauscher B, Seppi K, Ulmer H, Poewe W.

Neurology. 2002 Dec 10;59(11):1705-7.

PMID:
12473756
20.

Effects of immobility on sensory and motor symptoms of restless legs syndrome.

Michaud M, Lavigne G, Desautels A, Poirier G, Montplaisir J.

Mov Disord. 2002 Jan;17(1):112-5.

PMID:
11835447

Supplemental Content

Support Center